Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease

NCT01680965 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

44

Enrollment

OTHER

Sponsor class

Conditions

Chronic Graft Versus Host Disease

Interventions

DRUG: Ofatumumab

Sponsor

H. Lee Moffitt Cancer Center and Research Institute